Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers
Sponsor: Immunocore Ltd
Summary
This phase 1/2 first-in-human study is designed to test the safety and efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a single agent and in combination with other therapies in HLA-A\*02:01-positive participants with selected advanced PIWIL1-Positive cancers.
Official title: A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-R117C (PIWIL1 × CD3 ImmTAC® Bispecific Protein) as a Single Agent and in Combination in HLA-A*02:01-Positive Participants With Selected Advanced PIWIL1-Positive Cancers
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
600
Start Date
2024-01-10
Completion Date
2027-11-30
Last Updated
2026-01-28
Healthy Volunteers
No
Conditions
Interventions
IMC-R117C
IV infusion
Chemotherapy drug
IV infusion
Chemotherapy drug
oral
Kinase inhibitor
oral
Antiangiogenic Agent
IV infusion
Monoclonal antibody
IV infusion
Locations (13)
St Vincent's Hospital
Darlinghurst, Sydney, Australia
Peter MacCallum Cancer Centre
Melbourne, Australia
Institut Jules Bordet
Anderlecht, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
UZ Leuven
Leuven, Belgium
Universitaetsklinikum Heidelberg
Heidelberg, Germany
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, Italy
nstituto Clinico Humanitas
Rozzano, Italy
Antoni van Leeuwenhoek
Amsterdam, Netherlands
Hospital HM Nou Delfos
Barcelona, Spain
VHIO, Vall d'Hebron University Hospital
Barcelona, Spain
Centro Integral Oncologico Clara Campal
Madrid, Spain
Hospital Universitario Fundacion Jimenez Diaz
Madrid, Spain